Foxp3 expression in CD4⁺CD25⁺Foxp3⁺ regulatory T cells promotes development of colorectal cancer by inhibiting tumor immunity

Abstract

The mechanism underlying CD4⁺CD25⁺Foxp3⁺ regulatory T cells (Tregs) promoting the development of colorectal cancer (CRC) was elucidated in the present study. Forty-eight cases of colorectal carcinomas, 22 cases of colon polyps and 21 cases of normal colorectal tissues were collected. The correlation among Foxp3, IL-10 and Stat3, and the clinical relevance of these three indexes were analyzed. The results showed that the levels of Foxp3 expressed in infiltrating CD4⁺CD25⁺Foxp3⁺Tregs, and IL-10 and Stat3 in CRC tissues were all significantly higher than those in polypus tissues and normal colon tissues (P< 0.01). Pearson correlation analysis indicated that the expression level of Foxp3 was positively correlated with Stat3 at mRNA level (r=0.526, P=0.036), and was positively correlated with IL-10 at protein level (r=0.314, P=0.030). The Foxp3 expressed in CD4⁺CD25⁺Foxp3⁺Tregs was correlated with the histological grade, lymph node metastasis and TNM stage of CRC (P<0.05 for all). The IL-10 expression was correlated with the histological grade and TNM stage (both P<0.05). The Stat3 expression was correlated with the lymph node metastasis and TNM stage (both P<0.05). It was concluded that CD4⁺CD25⁺Foxp3⁺Tregs can inhibit tumor immunity in combination with some other related inhibitory cytokines and that Foxp3 expression in CD4⁺CD25⁺Foxp3⁺Tregs correlates with CRC progression.

Keywords

CD4⁺CD25⁺Foxp3⁺ regulatory T cells / Foxp3 / Stat3 / IL-10 / colorectal cancer / tumor immunity

References

[1] ZhengY, JosefowiczS, ChaudhryA, et al. . Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T cell fate. Nature, 2010, 463(7282): 808-812 PMID: 20072126 PMCID: 2884187

[2] WhitesideTL. What are regulatory T cells (Treg) regulating in cancer and why?. Semin Cancer Biol, 2012, 22(4): 327-334 PMID: 22465232 PMCID: 3385925

[3] BettsG, JonesE, JunaidS, et al. . Suppression of tumor-specific CD4+ T cells is associated with progression of human colorectal cancer. Gut, 2012, 61(8): 1163-1171 PMID: 22207629

[4] MuzesG, MolnarB, SiposF. Regulatory T cells in inflammatory bowel diseases and colorectal cancer. World J Gastrownterol, 2012, 18(40): 5688-5694

[5] SalamaP, PhillipsM, GrieuF, et al. . Tumor infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol, 2009, 27(2): 186-192 PMID: 19064967

[6] WhitesideTL. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?. Cancer Immunol Immunother, 2014, 63(1): 67-72 PMID: 24213679

[7] TaoH, MimuraY, AoeK, et al. . Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer, 2012, 75(1): 95-101 PMID: 21719142

[8] LadoireS, ArnouldL, MignotG, et al. . Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat, 2011, 125(1): 65-72 PMID: 20229175

[9] XuW, LiuT, SongJ, et al. . The appearance of Tregs in cancer nest is a promising independent risk factor in colon cancer. J Cancer Res Clin Oncol, 2013, 139(11): 1845-1852 PMID: 24005418

[10] Cross-KnorrS, LuSL, PerezK, et al. . RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients. BMC Cancer, 2013, 13: 463 PMID: 24098947 PMCID: 3856511

[11] LinYC, MahalingamJ, ChiangJM, et al. . Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer. Int J Cancer, 2013, 132(6): 1341-1350 PMID: 22907255

[12] GrimmingT, KimM, GermerCT, et al. . The role of Foxp3 in disease progression in colorectal cancer patients. Oncoimmunology, 2013, 2(6): 24521

[13] HoriS, NomuraT, SakaguchiS. Control of regulatory T cell development by the transcription factor FOXP3. Science, 2003, 299(5609): 1057-1061 PMID: 12522256

[14] WalkerMR, KasprowiczDJ, GersukVH, et al. . Induction of FOXP3 and acquisition of T regulatory activity by stimulated human CD4+CD25-T cells. J Clin Invest, 2003, 112(9): 1437-1443 PMID: 14597769

[15] GirardinA, McCallJ, BlackMA, et al. . Inflammatory and regulatory T cells contribute to a unique immune microenvironment in tumor tissue of colorectal cancer patients. Int J Cancer, 2013, 132(8): 1842-1850 PMID: 23002055

[16] KimM, GrimmigT, GrimmM, et al. . Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer. PLoS One, 2013, 8(1): 53630

[17] YoonHH, OrrockJM, FosterNR, et al. . Prognostic impact of Foxp3 regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS One, 2012, 7(8): 42274

[18] WhitesideTL. The tumor microenvironment and its role in promoting tumor growth. Oncogene, 2008, 27(45): 5904-5912 PMID: 18836471 PMCID: 3689267

[19] ImaiN, IkedaH, TawaraI, et al. . Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells. Eur J Immunol, 2009, 39(1): 241-253 PMID: 19089817

[20] WolfD, WolfAM, RumpoldH, et al. . The expression of the regulatory T cell-specific forkhead box transcription factor Foxp3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res, 2005, 11(23): 8326-8331 PMID: 16322292

[21] Zizi-SermpetzoglouA, SavvaidouV, MyoteriD, et al. . Expression of pSTAT3 in human colorectal carcinoma: correlation with clinico-pathological parameters. J BUON, 2012, 17(4): 691-694 PMID: 23335526

[22] FletcherS, TurksonJ, GunningPT. Molecular approaches towards the inhibition of the signal transducer and activator of transcription3 (Stat3) protein. Chem Med Chen, 2008, 3(8): 1159-1168

[23] AI Zaid SiddiqueeK, TurksonJ. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res, 2008, 18(2): 254-267 PMID: 18227858

[24] YuH, KortvlewSM, PardollD. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol, 2007, 7(1): 41-51 PMID: 17186030

[25] ChenZ, HanZC. STAT3: a critical transcription activator in angiogenesis. Med Res Rev, 2008, 28(2): 185-200 PMID: 17457812

[26] FrankDA. STAT 3 as a central mediator of neoplastic cellular transformation. Cancer Lett, 2007, 251(2): 199-210 PMID: 17129668

[27] GordzielC, BratschJ, MorigglR, et al. . Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma. Br J Cancer, 2013, 109(1): 138-146 PMID: 23756862 PMCID: 3708576

[28] ZhangJ, LuY, YueX, et al. . MiR-124 suppresses growth of human colorectal by inhibiting STAT3. PLoS One, 2013, 8(8): 70300

[29] DennisKL, BlatnerNR, GounariF, et al. . Current status of interleukin-10 and regulatory T-cells in cancer. Curr Opin Oncol, 2013, 25(6): 637-645 PMID: 24076584 PMCID: 4322764

[30] SchmidtMA, FortschC, SchmidtM, et al. . Circulating regulatory T cells of cancer patients receiving radiochemotherapy may be useful to individualize cancer treatment. Radiother Oncol, 2012, 104(1): 131-138 PMID: 22682747